Healthcare / BiotechnologyNasdaqCM
$0.68
-0.01 (-0.88%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-33.1M · quality 68.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
23/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$23M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-95.4%
↓Gross Margin
N/A
•Debt/Equity
N/A
•TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2015–2025 · 10 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-5811.2%
FCF / Net income
1.25x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $570000.0 · net income $-26.5M · FCF $-33.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | $570000.00 | $570000.00 | $501000.00 | $424000.00 | $477000.00 | $931000.00 | $21.0M | $443000.00 | $3.6M | — | — | — |
| Net Income | $-26.5M | $-26.5M | $-39.8M | $-28.5M | $-23.2M | $-73.3M | $-255.6M | $-95.2M | $-74.2M | $-29.1M | $-14.1M | $-4.6M |
| EBITDA | $-29.7M | $-29.7M | $-43.6M | $-29.3M | $-34.2M | $-38.8M | $-252.2M | $-95.5M | $-74.6M | — | — | — |
| EPS | — | — | -0.93 | -2.78 | -7.28 | -25.64 | 141.84 | — | — | — | — | — |
| Operating Margin | -5219.1% | -5219.1% | -8710.0% | -6900.5% | -7189.7% | -4179.5% | -1203.0% | -21641.8% | -2083.2% | — | — | — |
| Net Margin | -4646.1% | -4646.1% | -7950.9% | -6710.4% | -4865.8% | -7876.4% | -1217.4% | -21484.9% | -2062.9% | — | — | — |
| Balance Sheet | ||||||||||||
| Debt/Equity | — | — | 0.00 | 0.00 | — | 0.00 | 0.88 | 1.86 | — | — | — | — |
| Current Ratio | 20.86 | 20.86 | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||
| Free Cash Flow | $-33.1M | $-33.1M | $-34.1M | $-25.3M | $-29.2M | $-56.4M | $-137.2M | $-74.5M | $-69.2M | $-28.2M | $-2.3M | $-4.2M |
| Returns | ||||||||||||
| ROE | -95.4% | -95.4% | -76.5% | -32.1% | -74.4% | -150.8% | -681.6% | -541.6% | -80.5% | -42.4% | 47.8% | 28.9% |
| Valuation | ||||||||||||
| P/B | 0.81 | 0.81 | 2.83 | 0.25 | 0.42 | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||
| Revenue Growth | 13.8% | 13.8% | 18.2% | -11.1% | — | -95.6% | 4638.8% | -87.7% | — | — | — | — |
| EPS Growth | — | — | 66.5% | 61.8% | — | -118.1% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.0%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.93 → n/d
Residual
-27.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.